Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AR-301 added to antibiotics for ventilator-associated Staphylococcus aureus pneumonia
MOH_2019-06-12_007199Phase 3Recruiting
- Sponsor
- Aridis Pharmaceuticals, Inc.
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tosatoxumab in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Aridis Pharmaceuticals, Inc. Started Jun 2019; status: recruiting.
02
Drugs
tosatoxumab
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on MOH_2019-06-12_007199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-12_007199.